Gene therapy aims to treat or prevent disease by introducing, altering, or silencing genes within a patient's cells. The "one and done" claim is an aspiration that, once the therapeutic gene is introduced and functioning properly, a single administration could yield lifelong benefits. However, it's not always that simple.
Firstly, the issue of transgene expression waning over time is a significant consideration. In gene therapy, a therapeutic gene (transgene) is introduced into the patient's cells. It's hoped that this gene will produce its beneficial effects indefinitely, but in reality, long-term expression can be challenging. Factors such as the patient's age, the type of cells targeted, and the specific disease can all influence how long the transgene remains functional.
Secondly, the problem of potential immunogenicity, particularly with virus-based gene therapies, is a significant concern. Viruses, despite being modified to be harmless, can still trigger immune responses. This can not only limit the effectiveness of the initial therapy but also prevent the same viral vector from being used again, as the body has developed an immune response to it. This makes redosing or re-administering the same viral-based therapy difficult.
These factors are among the challenges currently being addressed in gene therapy research. Solutions such as non-viral delivery systems, immune modulation strategies, and different viral vectors are being explored. It's a rapidly evolving field, and while the potential of gene therapy is enormous, it's a complex task that requires careful consideration of numerous factors to ensure both efficacy and safety.
The challenges associated with viral vectors for gene therapy, such as immunogenicity, have spurred interest in non-viral alternatives. These alternatives can broadly be divided into physical methods and chemical methods.
Physical methods include microinjection, gene gun, electroporation, and sonoporation, which involve directly inserting genetic material into the cell using physical force. While these methods are effective in certain scenarios, they can be quite invasive and potentially damaging to the cells.
Chemical methods, on the other hand, involve the use of synthetic carriers to deliver the genes. These carriers can be lipids (in the case of liposomes), polymers, or even inorganic nanoparticles.
As per Dr. Leaf Huang, Fred Eshelman Distinguished Professor at the Eshelman School of Pharmacy, University of North Carolina, "Liposomes are one of the most advanced non-viral gene carriers in terms of clinical development. The lipid nanoparticles can be very effectively taken up by the target cells in the liver."
One company that has leveraged the potential of lipid nanoparticles for gene delivery is Moderna Therapeutics. They have made waves in recent years with their mRNA technology, particularly with their COVID-19 vaccine. However, they're also developing treatments for genetic disorders using the same technology.
Similarly, Alnylam Pharmaceuticals has successfully developed and marketed ONPATTRO (patisiran), the first-ever RNA interference (RNAi) therapeutic, which is enclosed in a lipid nanoparticle to target liver cells. The drug treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, a rare genetic disease.
Precision NanoSystems is another noteworthy company that develops lipid nanoparticle delivery systems for gene therapy and has multiple ongoing partnerships with pharmaceutical companies for drug development.
While promising, non-viral gene therapy still faces challenges such as lower gene transfer efficiency compared to viral methods and difficulties in targeting specific cells. However, research is ongoing, and advancements are continuously being made to address these limitations.
Comments